Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LXP107
- Development stage
- Preclinical
- Lead developer
- LaunXP Biomedical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LXP107 (formerly known as LXPA1988 and DCBC01901) is an orally active, selective small-molecule inhibitor of FMS-like tyrosine kinase 3 (FLT3) and its mutant forms, including FLT3-ITD and FLT3-D835Y. Originally developed by the Development Center for Biotechnology (DCB) in Taiwan and subsequently licensed to LaunXP Biomedical, LXP107 is designed to block aberrant FLT3-driven signaling pathways. In preclinical models of FLT3-mutated acute myeloid leukemia (AML), LXP107 has demonstrated potent anti-tumor activity and complete tumor regression. It is currently in preclinical development for the treatment of FLT3-mutated AML.
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on LXP107.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LXP107.